Quantcast
Last updated on April 20, 2014 at 8:10 EDT

Latest Lamotrigine Stories

2009-03-02 23:00:00

BRANFORD, Conn., March 3 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. today announced that it met its primary endpoint for its Phase 2 clinical trial investigating the safety and efficacy of ganaxolone as adjunctive therapy in adults with partial onset seizures, a type of epilepsy. In this trial, ganaxolone demonstrated a statistically significant reduction in seizures versus placebo. Efficacy was seen in the first week of dosing. Ganaxolone was also found to be safe and well-tolerated in...

2009-01-28 07:00:00

PITTSBURGH, Jan. 28 /PRNewswire-FirstCall/ --Mylan Inc. (Nasdaq: MYL) today announced that its subsidiaries Mylan Pharmaceuticals Inc. and Genpharm ULC received final approvals from the U.S. Food and Drug Administration (FDA) for their Abbreviated New Drug Applications (ANDAs) for Lamotrigine Tablets. Genpharm also received final FDA approval for its ANDA for a separate Lamotrigine product, Lamotrigine Tablets Chewable Dispersible (CD). Mylan Pharmaceuticals' and Genpharm's ANDAs were...

2009-01-27 07:00:00

- Vimpat(R) demonstrated greater seizure reduction and improved seizure freedom versus placebo when added to first and second-generation antiepileptic drugs (AEDs) - Phase III study supports recent U.S. FDA and European Commission approvals of Vimpat(R) ATLANTA, Jan. 27 /PRNewswire-FirstCall/ -- The new antiepileptic drug Vimpat(R) (lacosamide) demonstrated significantly fewer seizures in adult partial-onset epilepsy patients whose seizures were inadequately controlled despite taking up to...

2009-01-07 07:00:00

UCB's Keppra XR Will Become the Gold Standard Adjunctive Treatment for Partial-Onset Epilepsy by 2012, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists would welcome an adjunctive antiepileptic drug (AED) that is administered once-daily. According to U.S. neurologists, a drug of this type would...

2009-01-05 08:00:00

However, AED Brands Facing Generic Competition Will be Dropped or Pushed to Tier Three of Many MCO Formularies, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the willingness of neurologists to prescribe generic anti-epileptic drugs (AEDs) varies dramatically by indication, affording branded AEDs protection in the epilepsy...

cf5433d33f12a6421789d7ec9ae20c6c1
2008-12-17 08:35:00

The drugs that cure epileptic seizures are known to increase the risk of suicide, and federal regulators decided Tuesday drug companies must clearly display that warning.The Food and Drug Administration made the announcement a year after the agency first said patients taking the drugs have a slightly higher risk for suicide than those taking dummy pills.One in 500 patients face an increased risk of suicidal thoughts and behavior while taking the drugs. The new warning emphasizes that risks...

2008-12-16 14:56:47

The U.S. Food and Drug Administration says it will require suicide warnings on all anti-epileptic drugs, including those used to treat other conditions. The federal agency says the warning about the risk of suicidal thoughts and suicidality will be required on all anti-epileptic drugs that are also used to treat psychiatric disorders, migraine headaches and other conditions. The warnings will appear on all prescribing information or labeling. Patients being treated with anti-epileptic drugs...

2008-12-08 13:12:00

ATLANTA, Dec. 8 /PRNewswire/ -- UCB today announced new findings from analyses of pooled Vimpat(R) (lacosamide) clinical trial data, demonstrating that the new antiepileptic drug (AED) starts working during the first week of treatment and across doses in a challenging patient population, when administered as adjunctive therapy. The analyses also showed that Vimpat(R) provides consistent seizure reduction versus placebo, when added to concomitant AEDs, and that it is generally...

2008-12-03 07:00:00

WALTHAM, Mass., Dec. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the modest introduction of emerging therapies in the bipolar depression market will not compensate for extensive generic erosion of branded agents, resulting in a decrease of just over $1 billion in drug sales through 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new...

2008-12-05 08:54:35

The cause of autism remains a mystery to the medical community, but researchers have found a link between an epilepsy drug and an increased risk of a child developing autism.A new study shows women who take the epilepsy drug valproate while pregnant may significantly increase their unborn baby's risk of developing autism.In an ongoing study conducted by the Liverpool and Manchester Neurodevelopment Group, researchers are examining 632 children, about half of whom were exposed to epilepsy...